PRA Health Sciences Inc. (NASDAQ:PRAH) shares rose 1.9% during trading on Friday . The company traded as high as $51.42 and last traded at $51.40, with a volume of 361,309 shares trading hands. The stock had previously closed at $50.44.

PRAH has been the topic of a number of recent research reports. Jefferies Group reiterated a “buy” rating and issued a $57.00 price objective on shares of PRA Health Sciences in a research report on Friday, July 29th. KeyCorp upgraded PRA Health Sciences from a “sector weight” rating to an “overweight” rating and set a $55.00 price objective on the stock in a research report on Monday, June 13th. Zacks Investment Research lowered PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, August 11th. Credit Suisse Group AG initiated coverage on PRA Health Sciences in a research report on Monday, June 20th. They issued a “neutral” rating and a $43.00 price objective on the stock. Finally, First Analysis initiated coverage on PRA Health Sciences in a research report on Monday, June 20th. They issued an “equal weight” rating and a $47.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $48.94.

The firm has a 50-day moving average of $47.28 and a 200-day moving average of $45.02. The firm has a market cap of $3.13 billion and a PE ratio of 44.01.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $394.20 million for the quarter, compared to analyst estimates of $381.25 million. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 earnings per share. Equities research analysts predict that PRA Health Sciences Inc. will post $2.46 EPS for the current year.

In other PRA Health Sciences news, VP David W. Dockhorn sold 107,257 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $49.00, for a total transaction of $5,255,593.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Colin Shannon sold 113,133 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $51.57, for a total transaction of $5,834,268.81. Following the transaction, the chief executive officer now owns 120,000 shares of the company’s stock, valued at $6,188,400. The disclosure for this sale can be found here.

An institutional investor recently raised its position in PRA Health Sciences stock. Bank of Montreal Can boosted its stake in shares of PRA Health Sciences Inc. (NASDAQ:PRAH) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 231,826 shares of the company’s stock after buying an additional 25,738 shares during the period. Bank of Montreal Can owned about 0.38% of PRA Health Sciences worth $10,495,000 at the end of the most recent reporting period.

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.